Pfizer Overpays for Seagen, but Who's Counting
Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive.
Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive.